Table 1 Clinicopathological characteristics and prognostic factors of 161 patients with OSCC measured by negative and positive Apo10 and TKTL1 expressors
Characteristics | Number of patients | p-value | Number of patients | p-value | |||
|---|---|---|---|---|---|---|---|
Total | Apo10 expression | Apo10 expression | TKTL1 expression | TKTL1 expression | |||
negative (<10%) | positive (≥10%) | negative (<10%) | positive (≥10%) | ||||
n = 161 | n = 29 (18%) | n = 132 (82%) | n = 93 (58%) | n = 68 (42%) | |||
Age (y) | 0.5445 | 0.7507 | |||||
<60 ± 11.8 | 80 (49.7%) | 16 (20%) | 64 (80%) | 45 (56%) | 35 (44%) | ||
≥60 ± 11.8 | 81 (50.3%) | 13 (16%) | 68 (84%) | 48 (59%) | 33 (41%) | ||
Gender | 0.8016 | 0.4501 | |||||
Male | 122 (75.8%) | 23 (19%) | 99 (81%) | 73 (60%) | 49 (40%) | ||
Female | 39 (24.2%) | 6 (15%) | 33 (85%) | 20 (51%) | 19 (49%) | ||
Site distribution of OSCC | 0.8991 | 0.8782 | |||||
Lips | 11 (6.8%) | 3 (27%) | 8 (73%) | 9 (82%) | 2 (18%) | ||
Tongue | 41 (25.5%) | 8 (20%) | 33 (80%) | 21 (51%) | 20 (49%) | ||
Floor of the mouth | 64 (39.8%) | 10 (16%) | 54 (84%) | 37 (58%) | 27 (42%) | ||
Palate | 15 (9.3%) | 0 (0%) | 15 (100%) | 6 (40%) | 9 (60%) | ||
Buccal mucosa | 8 (5.0%) | 3 (38%) | 5 (62%) | 6 (75%) | 2 (15%) | ||
Alveolar ridge | 22 (13.7%) | 5 (23%) | 17 (77%) | 14 (64%) | 8 (36%) | ||
Histological Grading | 0.4765* | 0.7396* | |||||
G1 | 41 (25.5%) | 10 (24%) | 31 (76%) | 23 (56%) | 18 (44%) | ||
G2 | 106 (65.8%) | 15 (14%) | 91 (86%) | 63 (59%) | 43 (41%) | ||
G3 | 13 (8.1%) | 3 (23%) | 10 (77%) | 6 (46%) | 7 (54%) | ||
G4 | 1 (0.6%) | 1 (100%) | 0 (0%) | 1 (100%) | 0 (0%) | ||
Tumor size | 0.0194** | 0.0018** | |||||
pT1 | 64 (39.8%) | 14 (22%) | 50 (78%) | 46 (72%) | 18 (28%) | ||
pT2 | 42 (26.1%) | 11 (26%) | 31 (74%) | 25 (59%) | 17 (41%) | ||
pT3 | 17 (10.6%) | 0 (0%) | 17 (100%) | 5 (29%) | 12 (71%) | ||
pT4 | 38 (23.6%) | 4 (11%) | 34 (89%) | 17 (45%) | 21 (55%) | ||
Cervical lymph node metastasis | 0.5638 | 0.0008 | |||||
pN0 | 118 (73.3%) | 23 (19%) | 95 (81%) | 78 (66%) | 40 (34%) | ||
pN1-3 | 43 (26.7%) | 6 (14%) | 37 (86%) | 15 (35%) | 28 (65%) | ||
UICC stage | 0.0025*** | <0.0001*** | |||||
UICC I | 48 (29.8%) | 12 (25%) | 36 (75%) | 42 (88%) | 6 (12%) | ||
UICC II | 36 (22.4%) | 11 (31%) | 25 (69%) | 23 (64%) | 13 (36%) | ||
UICC III | 31 (19.3%) | 1 (3%) | 30 (97%) | 11 (35%) | 20 (65%) | ||
UICC IV | 46 (28.6%) | 5 (11%) | 41 (89%) | 17 (37%) | 29 (63%) | ||
Locoregional recurrence | 0.0125 | <0.0001 | |||||
No | 117 (72.7%) | 27 (23%) | 90 (77%) | 81 (69%) | 36 (31%) | ||
Yes | 44 (27.3%) | 2 (5%) | 42 (95%) | 12 (27%) | 32 (73%) | ||
Extracapsular spreading of lymph nodes | 0.0452 | 0.0099 | |||||
No | 143 (88,8%) | 29 (20%) | 114 (80%) | 88 (62%) | 55 (38%) | ||
Yes | 18 (11,2%) | 0 (0%) | 18 (100%) | 5 (28%) | 13 (72%) | ||
Adjuvant therapy (RTx, Ctx) | 0.1202 | 0.6337 | |||||
No | 111 (68,9%) | 24 (22%) | 87 (78%) | 66 (59%) | 45 (41%) | ||
Yes | 50 (31,1%) | 5 (5%) | 45 (95%) | 27 (54%) | 23 (46%) | ||